Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(2)

Detailed Status

Completed2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

completed250%

terminated250%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02652871

terminatedphase_1

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

NCT02737072

completedphase_2

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

NCT01439568

terminatedphase_2

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01391130

Clinical Trials (4)

Showing 4 of 4 trials

NCT02652871Phase 1

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed

NCT02737072Phase 1

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Terminated

NCT01439568Phase 2

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Completed

NCT01391130Phase 2

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4